Free Trial

Eyenovia Q1 2024 Earnings Report

Eyenovia logo
$0.96 -0.15 (-13.50%)
As of 03:58 PM Eastern

Eyenovia EPS Results

Actual EPS
-$14.40
Consensus EPS
-$14.40
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Eyenovia Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
$1.23 million
Beat/Miss
Missed by -$1.22 million
YoY Revenue Growth
N/A

Eyenovia Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Remove Ads

Eyenovia Earnings Headlines

Eyenovia enters non-binding LOI to effect reverse merger with Betaliq
Eyenovia Shares Drop 14% Amid Betaliq Merger Talks
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
See More Eyenovia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eyenovia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eyenovia and other key companies, straight to your email.

About Eyenovia

Eyenovia (NASDAQ:EYEN), an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

View Eyenovia Profile

More Earnings Resources from MarketBeat